|
G |
Apob |
apolipoprotein B |
multiple interactions |
EXP |
[3-deazaadenosine co-treated with Ethanolamine] results in decreased secretion of APOB protein alternative form; [Bezafibrate co-treated with Ethanolamine] results in decreased secretion of APOB protein alternative form; [Clofibric Acid co-treated with Ethanolamine] results in decreased secretion of APOB protein alternative form |
CTD |
PMID:8944747 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
EXP |
[3-deazaadenosine co-treated with Ethanolamine] results in decreased secretion of APOE protein; [Bezafibrate co-treated with Ethanolamine] results in decreased secretion of APOE protein; [Clofibric Acid co-treated with Ethanolamine] results in decreased secretion of APOE protein |
CTD |
PMID:8944747 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Egf |
epidermal growth factor |
increases activity |
ISO |
Ethanolamine results in increased activity of EGF protein |
CTD |
PMID:15802876 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
increases activity |
ISO |
Ethanolamine results in increased activity of FGF1 protein |
CTD |
PMID:15802876 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Pnliprp2 |
pancreatic lipase related protein 2 |
increases metabolic processing |
EXP |
PNLIPRP2 protein results in increased metabolism of Ethanolamine |
CTD |
PMID:9822688 |
|
NCBI chr 1:257,897,766...257,916,434
Ensembl chr 1:257,897,766...257,916,434
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases export |
ISO |
ABCB1 protein results in increased export of anandamide |
CTD |
PMID:30102254 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein |
CTD |
PMID:30610963 PMID:34756920 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ACOX1 mRNA] |
CTD |
PMID:34756920 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Agpat2 |
1-acylglycerol-3-phosphate O-acyltransferase 2 |
multiple interactions |
ISO |
anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of AGPAT2 mRNA] |
CTD |
PMID:34756920 |
|
NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371
|
|
G |
App |
amyloid beta precursor protein |
decreases response to substance decreases metabolic processing decreases abundance |
EXP ISO |
anandamide results in decreased susceptibility to APP protein APP protein results in decreased metabolism of anandamide APP protein results in decreased abundance of anandamide |
CTD |
PMID:22233683 PMID:26976670 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions decreases activity |
ISO |
AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein] |
CTD |
PMID:19022239 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
anandamide results in increased cleavage of CASP3 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein] |
CTD |
PMID:26513129 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
anandamide results in increased expression of CD36 mRNA; anandamide results in increased expression of CD36 protein |
CTD |
PMID:17360047 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
decreases expression |
ISO |
anandamide results in decreased expression of CGA mRNA |
CTD |
PMID:30610963 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
affects activity increases response to substance decreases expression affects binding increases activity multiple interactions |
ISO EXP |
anandamide affects the activity of CNR1 protein CNR1 protein results in increased susceptibility to anandamide anandamide results in decreased expression of CNR1 protein anandamide binds to CNR1 protein anandamide results in increased activity of CNR1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1] [anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; [CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of anandamide; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]] |
CTD |
PMID:10871313 PMID:11408034 PMID:11891798 PMID:12657697 PMID:14504685 PMID:15453094 PMID:17557913 PMID:19147270 PMID:29730318 PMID:31024316 PMID:31199905 PMID:36858108 More...
|
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
affects activity affects binding multiple interactions |
ISO EXP |
anandamide affects the activity of CNR2 protein anandamide binds to CNR2 protein anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide] |
CTD |
PMID:10617657 PMID:10688601 PMID:15453094 PMID:19147270 PMID:30102254 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases phosphorylation |
ISO |
anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]] anandamide results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:30610963 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
decreases abundance |
ISO |
CRH protein results in decreased abundance of anandamide |
CTD |
PMID:26821211 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
multiple interactions increases metabolic processing |
ISO |
cannabichromene inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabidiol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; cannabigerol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; delta-8-tetrahydrocannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Dronabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide] |
CTD |
PMID:29689453 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein] |
CTD |
PMID:21949157 PMID:26513129 PMID:29441458 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO |
anandamide results in increased phosphorylation of EIF2S1 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:26513129 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Ervfrd-1 |
endogenous retrovirus group FRD member 1, envelope |
decreases expression |
ISO |
anandamide results in decreased expression of ERVFRD-1 mRNA |
CTD |
PMID:30610963 |
|
NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases expression |
ISO |
anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] anandamide results in increased expression of F3 protein |
CTD |
PMID:27556861 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Faah |
fatty acid amide hydrolase |
increases degradation increases response to substance decreases metabolic processing multiple interactions affects expression |
ISO EXP |
FAAH results in increased degradation of anandamide FAAH gene mutant form results in increased susceptibility to anandamide FAAH gene mutant form results in decreased metabolism of anandamide FAAH protein results in increased degradation of anandamide [Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; FAAH protein results in increased metabolism of and results in decreased activity of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide]; Silybin inhibits the reaction [FAAH protein results in increased metabolism of and results in decreased activity of anandamide] anandamide affects the expression of FAAH protein [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; Rimonabant inhibits the reaction [FAAH gene mutant form results in increased susceptibility to anandamide] |
CTD |
PMID:11556820 PMID:16131814 PMID:16886060 PMID:19515121 PMID:20702753 PMID:23761300 PMID:26642910 PMID:27307500 PMID:27385208 PMID:29787777 PMID:31121907 PMID:37245739 More...
|
|
NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions affects abundance affects binding |
EXP ISO |
11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein] FABP1 protein affects the abundance of anandamide FABP1 protein affects the reaction [Dronabinol results in increased abundance of anandamide]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide] |
CTD |
PMID:29414765 PMID:30232874 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein] anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein |
CTD |
PMID:9748483 PMID:15601931 PMID:19515121 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B] |
CTD |
PMID:12813001 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
anandamide results in increased expression of IGF1 protein |
CTD |
PMID:17307377 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:15748152 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] |
CTD |
PMID:12813001 PMID:15748152 PMID:27556861 PMID:30611738 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:30611738 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lep |
leptin |
decreases abundance multiple interactions decreases activity decreases transport |
ISO |
LEP protein results in decreased abundance of anandamide Dietary Fats inhibits the reaction [LEP protein results in decreased abundance of anandamide] LEP protein results in decreased activity of anandamide LEP protein results in decreased transport of anandamide |
CTD |
PMID:16154199 PMID:29967158 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] anandamide results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:19477951 PMID:21179406 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] anandamide results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:19477951 PMID:21179406 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
anandamide results in increased expression of MMP1 mRNA |
CTD |
PMID:16330497 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases expression |
ISO |
anandamide results in increased expression of MMP3 mRNA |
CTD |
PMID:16330497 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of MMP9 mRNA] |
CTD |
PMID:16330497 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:11891798 PMID:15748152 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
anandamide results in increased cleavage of PARP1 protein |
CTD |
PMID:29441458 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
anandamide binds to and results in increased activity of PPARA protein |
CTD |
PMID:17906680 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression increases metabolic processing |
EXP ISO |
[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein PTGS2 results in increased metabolism of anandamide [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide] |
CTD |
PMID:16330497 PMID:17245358 PMID:20702753 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
anandamide inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased expression of SELP protein] anandamide results in increased expression of SELP protein |
CTD |
PMID:27151562 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of TIMP1 mRNA N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16330497 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases abundance |
EXP ISO |
anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein] TNF protein results in increased abundance of anandamide anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF] |
CTD |
PMID:12509806 PMID:12813001 PMID:20626112 PMID:30611738 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases response to substance increases activity affects response to substance affects binding |
ISO EXP |
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein] TRPV1 protein results in increased susceptibility to anandamide anandamide results in increased activity of TRPV1 protein 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein] anandamide binds to TRPV1 protein |
CTD |
PMID:11140687 PMID:11278420 PMID:14504685 PMID:15453094 PMID:15601931 PMID:15615864 PMID:17038422 PMID:17913835 PMID:18550765 PMID:21949157 More...
|
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
anandamide results in decreased expression of and results in decreased secretion of VEGFA protein |
CTD |
PMID:15313899 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
chloroprocaine results in increased expression of BAX protein LINC00494 inhibits the reaction [chloroprocaine results in increased expression of BAX protein] |
CTD |
PMID:37650745 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression multiple interactions |
ISO |
chloroprocaine results in decreased expression of CCND1 protein LINC00494 inhibits the reaction [chloroprocaine results in decreased expression of CCND1 protein] |
CTD |
PMID:37650745 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Med19 |
mediator complex subunit 19 |
decreases expression multiple interactions |
ISO |
chloroprocaine results in decreased expression of MED19 mRNA; chloroprocaine results in decreased expression of MED19 protein LINC00494 inhibits the reaction [chloroprocaine results in decreased expression of MED19 mRNA]; LINC00494 inhibits the reaction [chloroprocaine results in decreased expression of MED19 protein] |
CTD |
PMID:37650745 |
|
NCBI chr 3:69,762,138...69,772,661
Ensembl chr 3:69,762,166...69,772,036
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression multiple interactions |
ISO |
chloroprocaine results in decreased expression of PCNA protein LINC00494 inhibits the reaction [chloroprocaine results in decreased expression of PCNA protein] |
CTD |
PMID:37650745 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Dicyclomine inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Bad |
BCL2-associated agonist of cell death |
decreases expression |
ISO EXP |
diethanolamine results in decreased expression of BAD mRNA |
CTD |
PMID:16014740 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
EXP ISO |
diethanolamine results in decreased expression of BAX mRNA |
CTD |
PMID:16014740 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Calb1 |
calbindin 1 |
increases expression |
ISO |
diethanolamine results in increased expression of CALB1 mRNA |
CTD |
PMID:35812078 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Casp3 |
caspase 3 |
decreases expression increases activity |
ISO EXP |
diethanolamine results in decreased expression of CASP3 mRNA diethanolamine results in increased activity of CASP3 protein |
CTD |
PMID:16014740 PMID:18948303 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccnd2 |
cyclin D2 |
increases expression |
ISO EXP |
diethanolamine results in increased expression of CCND2 mRNA |
CTD |
PMID:16014740 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO EXP |
diethanolamine results in increased expression of CCNE1 mRNA |
CTD |
PMID:16014740 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression |
ISO EXP |
diethanolamine results in decreased expression of CDKN1A mRNA |
CTD |
PMID:16014740 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
decreases expression |
ISO EXP |
diethanolamine results in decreased expression of CDKN1B mRNA |
CTD |
PMID:16014740 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
E2f1 |
E2F transcription factor 1 |
increases expression |
ISO EXP |
diethanolamine results in increased expression of E2F1 mRNA |
CTD |
PMID:16014740 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
[diethanolamine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA |
CTD |
PMID:29594315 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Rrm2b |
ribonucleotide reductase regulatory TP53 inducible subunit M2B |
increases expression |
ISO |
diethanolamine results in increased expression of RRM2B mRNA |
CTD |
PMID:21704725 |
|
NCBI chr 7:69,077,024...69,108,742
Ensembl chr 7:69,078,291...69,108,633
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression |
ISO EXP |
diethanolamine results in decreased expression of TRP53 mRNA diethanolamine results in decreased expression of TP53 mRNA |
CTD |
PMID:16014740 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Wnt1 |
Wnt family member 1 |
increases expression |
ISO |
diethanolamine results in increased expression of WNT1 mRNA |
CTD |
PMID:35812078 |
|
NCBI chr 7:129,938,604...129,942,651
Ensembl chr 7:129,938,604...129,942,651
|
|
|
G |
Cat |
catalase |
affects response to substance |
ISO |
CAT protein affects the susceptibility to Etanidazole |
CTD |
PMID:2943713 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases export |
ISO |
ABCB1 protein results in increased export of N-oleoylethanolamine |
CTD |
PMID:30102254 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases response to substance multiple interactions |
ISO |
PPARA results in increased susceptibility to N-oleoylethanolamine N-oleoylethanolamine binds to and results in increased activity of PPARA protein |
CTD |
PMID:17906680 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
N-oleoylethanolamine results in decreased expression of PTGS2 protein |
CTD |
PMID:17906680 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
ISO |
benoxinate results in increased expression of AIFM1 protein |
CTD |
PMID:27590991 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
ISO |
benoxinate results in increased expression of BAX protein |
CTD |
PMID:27590991 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
benoxinate results in decreased expression of BCL2L1 protein |
CTD |
PMID:27590991 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Casp2 |
caspase 2 |
increases activity |
ISO |
benoxinate results in increased activity of CASP2 protein |
CTD |
PMID:27590991 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
benoxinate results in increased activity of CASP3 protein |
CTD |
PMID:27590991 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
benoxinate results in increased activity of CASP9 protein |
CTD |
PMID:27590991 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
benoxinate results in decreased activity of KCNH2 protein |
CTD |
PMID:28551711 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
benoxinate results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
benoxinate inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases export |
ISO |
ABCB1 protein results in increased export of palmidrol |
CTD |
PMID:30102254 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Apob |
apolipoprotein B |
affects folding |
ISO |
palmidrol affects the folding of APOB protein |
CTD |
PMID:16115474 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
multiple interactions |
ISO |
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Aqp4 |
aquaporin 4 |
affects expression |
ISO |
palmidrol affects the expression of AQP4 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856
|
|
G |
Cldn3 |
claudin 3 |
multiple interactions decreases expression |
ISO |
[TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA palmidrol results in decreased expression of CLDN3 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr12:21,708,538...21,710,010
Ensembl chr12:21,708,398...21,711,001
|
|
G |
Cldn5 |
claudin 5 |
decreases expression |
ISO |
palmidrol results in decreased expression of CLDN5 mRNA |
CTD |
PMID:31054246 |
|
NCBI chr11:82,212,822...82,214,248
Ensembl chr11:82,211,475...82,214,992
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP |
[rimonabant binds to and results in decreased activity of CNR1 protein] which results in decreased susceptibility to palmidrol analog |
CTD |
PMID:17558434 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
affects binding multiple interactions |
ISO EXP |
palmidrol binds to CNR2 protein [SR 144528 binds to and results in decreased activity of CNR2 protein] which results in decreased susceptibility to palmidrol analog |
CTD |
PMID:10617657 PMID:10688601 PMID:17558434 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
EXP |
palmidrol analog inhibits the reaction [[Streptozocin co-treated with iomeprol] results in increased expression of GSTA1 protein] |
CTD |
PMID:26474837 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[hempseed oil co-treated with palmidrol] results in decreased expression of IL10 mRNA |
CTD |
PMID:33722712 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[hempseed oil co-treated with palmidrol] results in decreased expression of IL6 mRNA |
CTD |
PMID:33722712 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
EXP |
palmidrol analog inhibits the reaction [[Streptozocin co-treated with iomeprol] results in increased expression of LCN2 protein] |
CTD |
PMID:26474837 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions affects localization |
EXP |
[MK-886 binds to and results in decreased activity of PPARA protein] which results in decreased susceptibility to palmidrol analog; [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] palmidrol affects the localization of PPARA protein |
CTD |
PMID:17558434 PMID:31787870 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[palmidrol co-treated with TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA; [TNF protein co-treated with IFNG protein co-treated with palmidrol] results in decreased expression of CLDN3 mRNA; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA]; palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in increased expression of AQP3 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
ISO |
palmidrol inhibits the reaction [[TNF protein co-treated with IFNG protein] results in decreased expression of TRPV1 mRNA] |
CTD |
PMID:31054246 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Procaine results in increased phosphorylation of AKT1 protein HRH1 protein affects the reaction [Procaine results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:32061592 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases expression |
ISO |
Procaine results in increased expression of ALPL mRNA |
CTD |
PMID:22083529 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases secretion |
ISO |
Procaine results in increased secretion of CALCA protein |
CTD |
PMID:18172555 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Capn1 |
calpain 1 |
multiple interactions |
ISO |
Procaine inhibits the reaction [Paraoxon results in increased expression of CAPN1 protein] |
CTD |
PMID:26998625 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Capn2 |
calpain 2 |
multiple interactions |
ISO |
Procaine inhibits the reaction [Paraoxon results in increased expression of CAPN2 protein] |
CTD |
PMID:26998625 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
ISO |
Procaine inhibits the reaction [Paraoxon results in increased expression of and affects the activity of CASP12 protein]; Procaine inhibits the reaction [Paraoxon results in increased expression of CASP12 protein] |
CTD |
PMID:20079824 PMID:26998625 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Procaine inhibits the reaction [Paraoxon results in increased expression of and affects the activity of CASP3 protein] |
CTD |
PMID:26998625 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cdh5 |
cadherin 5 |
decreases expression multiple interactions |
ISO |
Procaine results in decreased expression of CDH5 protein HRH1 protein affects the reaction [Procaine results in decreased expression of CDH5 protein] |
CTD |
PMID:32061592 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis |
ISO |
CES2 protein results in increased hydrolysis of Procaine |
CTD |
PMID:9300133 PMID:15475733 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Esr1 |
estrogen receptor 1 |
increases expression |
ISO |
Procaine results in increased expression of ESR1 mRNA |
CTD |
PMID:22083529 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Hrh1 |
histamine receptor H 1 |
multiple interactions affects binding |
ISO |
[HRH1 protein binds to Procaine] which results in increased import of Calcium; HRH1 protein affects the reaction [Procaine results in decreased expression of CDH5 protein]; HRH1 protein affects the reaction [Procaine results in increased phosphorylation of AKT1 protein]; HRH1 protein affects the reaction [Procaine results in increased phosphorylation of ITPR1 protein]; HRH1 protein affects the reaction [Procaine results in increased phosphorylation of MAPK1 protein]; HRH1 protein affects the reaction [Procaine results in increased phosphorylation of MAPK3 protein]; HRH1 protein affects the reaction [Procaine results in increased phosphorylation of PLCG1 protein]; HRH1 protein affects the reaction [Procaine results in increased transport of fluorescein isothiocyanate bovine serum albumin] |
CTD |
PMID:32061592 |
|
NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[Procaine co-treated with Paraoxon] results in increased expression of HSPA5 protein |
CTD |
PMID:26998625 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
increases phosphorylation multiple interactions |
ISO |
Procaine results in increased phosphorylation of ITPR1 protein HRH1 protein affects the reaction [Procaine results in increased phosphorylation of ITPR1 protein] |
CTD |
PMID:32061592 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Procaine results in increased phosphorylation of MAPK1 protein HRH1 protein affects the reaction [Procaine results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:32061592 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions |
ISO |
Procaine results in increased phosphorylation of MAPK3 protein HRH1 protein affects the reaction [Procaine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:32061592 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
Procaine results in increased activity of NR1I2 protein |
CTD |
PMID:25455453 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Plcg1 |
phospholipase C, gamma 1 |
increases phosphorylation multiple interactions |
ISO |
Procaine results in increased phosphorylation of PLCG1 protein HRH1 protein affects the reaction [Procaine results in increased phosphorylation of PLCG1 protein] |
CTD |
PMID:32061592 |
|
NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
increases activity |
EXP |
Procaine results in increased activity of TRPV1 protein |
CTD |
PMID:18172555 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|